One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy
Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved..
PURPOSE: To investigate 1-year outcomes of intravitreal aflibercept for polypoidal choroidal vasculopathy (PCV).
DESIGN: Retrospective, multicenter, consecutive case series.
PARTICIPANTS: A total of 90 eyes of 87 patients with treatment-naïve PCV followed at 3 tertiary centers.
METHODS: Clinical records were reviewed and imaging studies were analyzed of eyes with PCV that underwent 3 consecutive monthly aflibercept injections followed by injections every 2 months. Additional (rescue) injections were performed for worsening.
MAIN OUTCOME MEASURES: Best-corrected visual acuity (BCVA), optical coherence tomography (OCT), and angiographic findings at 1 year.
RESULTS: The mean BCVA (logarithm of the minimum angle of resolution units) of the 90 eyes improved from 0.31 at baseline to 0.17 at 12 months (P < 0.001). The mean central retinal thickness decreased from 315 μm at baseline to 204 μm at 12 months (P < 0.001). At 12 months, 64 eyes (71.1%) achieved a dry macula, defined as absence of intraretinal or subretinal fluid on OCT. Of 83 eyes that underwent indocyanine green angiography at both baseline and 12 months, 46 (55.4%) showed complete and 27 (32.5%) showed partial resolution of polypoidal lesions. Eleven of 82 eyes (13.4%) showed decreased size of branching choroidal vascular networks.
CONCLUSIONS: Intravitreal aflibercept administered over 1 year improved both visual acuity and macular morphology in a large number of treatment-naïve eyes with PCV.
| Errataetall: |
CommentIn: Ophthalmology. 2016 Feb;123(2):e13-4. - PMID 26802715 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:122 |
|---|---|
| Enthalten in: |
Ophthalmology - 122(2015), 9 vom: 19. Sept., Seite 1866-72 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yamamoto, Akiko [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.11.2015 Date Revised 21.03.2022 published: Print-Electronic CommentIn: Ophthalmology. 2016 Feb;123(2):e13-4. - PMID 26802715 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ophtha.2015.05.024 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM250095475 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM250095475 | ||
| 003 | DE-627 | ||
| 005 | 20231224155009.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ophtha.2015.05.024 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0833.xml |
| 035 | |a (DE-627)NLM250095475 | ||
| 035 | |a (NLM)26088619 | ||
| 035 | |a (PII)S0161-6420(15)00507-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamamoto, Akiko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.11.2015 | ||
| 500 | |a Date Revised 21.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Ophthalmology. 2016 Feb;123(2):e13-4. - PMID 26802715 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a PURPOSE: To investigate 1-year outcomes of intravitreal aflibercept for polypoidal choroidal vasculopathy (PCV) | ||
| 520 | |a DESIGN: Retrospective, multicenter, consecutive case series | ||
| 520 | |a PARTICIPANTS: A total of 90 eyes of 87 patients with treatment-naïve PCV followed at 3 tertiary centers | ||
| 520 | |a METHODS: Clinical records were reviewed and imaging studies were analyzed of eyes with PCV that underwent 3 consecutive monthly aflibercept injections followed by injections every 2 months. Additional (rescue) injections were performed for worsening | ||
| 520 | |a MAIN OUTCOME MEASURES: Best-corrected visual acuity (BCVA), optical coherence tomography (OCT), and angiographic findings at 1 year | ||
| 520 | |a RESULTS: The mean BCVA (logarithm of the minimum angle of resolution units) of the 90 eyes improved from 0.31 at baseline to 0.17 at 12 months (P < 0.001). The mean central retinal thickness decreased from 315 μm at baseline to 204 μm at 12 months (P < 0.001). At 12 months, 64 eyes (71.1%) achieved a dry macula, defined as absence of intraretinal or subretinal fluid on OCT. Of 83 eyes that underwent indocyanine green angiography at both baseline and 12 months, 46 (55.4%) showed complete and 27 (32.5%) showed partial resolution of polypoidal lesions. Eleven of 82 eyes (13.4%) showed decreased size of branching choroidal vascular networks | ||
| 520 | |a CONCLUSIONS: Intravitreal aflibercept administered over 1 year improved both visual acuity and macular morphology in a large number of treatment-naïve eyes with PCV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Coloring Agents |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 650 | 7 | |a VEGFA protein, human |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 650 | 7 | |a aflibercept |2 NLM | |
| 650 | 7 | |a 15C2VL427D |2 NLM | |
| 650 | 7 | |a Receptors, Vascular Endothelial Growth Factor |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Indocyanine Green |2 NLM | |
| 650 | 7 | |a IX6J1063HV |2 NLM | |
| 700 | 1 | |a Okada, Annabelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Kano, Mariko |e verfasserin |4 aut | |
| 700 | 1 | |a Koizumi, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Masaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Maruko, Ichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Sekiryu, Tetsuju |e verfasserin |4 aut | |
| 700 | 1 | |a Iida, Tomohiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ophthalmology |d 1993 |g 122(2015), 9 vom: 19. Sept., Seite 1866-72 |w (DE-627)NLM000457019 |x 1549-4713 |7 nnns |
| 773 | 1 | 8 | |g volume:122 |g year:2015 |g number:9 |g day:19 |g month:09 |g pages:1866-72 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ophtha.2015.05.024 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 122 |j 2015 |e 9 |b 19 |c 09 |h 1866-72 | ||